Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.96+1.30 (+6.97%)
At close: 04:00PM EST
20.00 +0.04 (+0.20%)
After hours: 07:54PM EST

Anavex Life Sciences Corp.

51 West 52nd Street
7th Floor
New York, NY 10019
United States
844 689 3939

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 25

Key executives

NameTitlePayExercisedYear born
Dr. Christopher U. MisslingChairman, Pres, CEO & Sec.671.6kN/A1966
Ms. Sandra Boenisch CPA, CPA, CGAPrincipal Financial Officer & Treasurer158.3kN/A1981
Mr. Stephan ToutainChief Operating OfficerN/AN/A1966
Dr. Emmanuel O. Fadiran RPh, Ph.D.Sr. VP of Regulatory AffairsN/AN/AN/A
Dr. Walter E. Kaufmann M.D.Chief Medical OfficerN/AN/AN/A
Clint TomlinsonVP of Corp.N/AN/AN/A
Dr. Adebayo Laniyonu Ph.D.Sr. VP of Nonclinical Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Corporate governance

Anavex Life Sciences Corp.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.